middle.news
Cleo Diagnostics Advances Ovarian Cancer Test Amid Rising Losses
3:52pm on Thursday 20th of August, 2026 AEST
•
Healthcare
Read Story
Cleo Diagnostics Advances Ovarian Cancer Test Amid Rising Losses
3:52pm on Thursday 20th of August, 2026 AEST
Key Points
Loss after tax increased 48.4% to $5.9 million
Revenues declined 31.6% to $232,000
Pivotal US clinical trial completed with 800+ participants
FDA pre-submission feedback positive; Analytical Validation underway
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE